<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559465</url>
  </required_header>
  <id_info>
    <org_study_id>2016_63</org_study_id>
    <secondary_id>2017-A02720-53</secondary_id>
    <nct_id>NCT03559465</nct_id>
  </id_info>
  <brief_title>Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.</brief_title>
  <acronym>SCLERO-LB</acronym>
  <official_title>Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      B Lymphocytes are thought to play an important role in the pathophysiology of systemic
      sclerosis. In this study, the profibrosing role of B lymphocytes of patients with systemic
      sclerosis will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B Lymphocytes of patients with systemic sclerosis will be assessed in term of interaction
      with fibroblasts from patients with systemic sclerosis and compared to healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroblast transcriptomic : myofibroblast signature</measure>
    <time_frame>36 months</time_frame>
    <description>expression of alpha Smooth Muscle Actin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroblast transcriptomic</measure>
    <time_frame>36 months</time_frame>
    <description>expression of COL1A1, COL1A2, COL3A1 by quantitative RT-PCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>patient with Scs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with SSc, (10 diffuse forms and 20 limited forms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subject</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <description>A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.
In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy.</description>
    <arm_group_label>patient with Scs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood punction</intervention_name>
    <description>1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte</description>
    <arm_group_label>healthy subject</arm_group_label>
    <arm_group_label>patient with Scs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients

          -  systemic sclerosis according to ACR-EULAR 2013

          -  written consent

          -  available insurance

        healthy controls

          -  written consent

          -  available insurance

        Exclusion Criteria:

        patients

          -  overlap with other connective tissue diseases

          -  immunosuppressants in the past 12 months

          -  corticosteroids ≥10mg/d

          -  pregnancy or breast feeding

        healthy controls

          -  systemic sclerosis according to ACR-EULAR 2013

          -  another connective tissue diseases

          -  immunosuppressants in the past 12 months

          -  corticosteroids ≥10mg/d

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Launay, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Launay, MD,PhD</last_name>
    <phone>3 20 44 42 95</phone>
    <phone_ext>+33</phone_ext>
    <email>david.launay@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Launay, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>B lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

